Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 4/2010

01-04-2010 | Translational Research and Biomarkers

Associations of MDM2 SNP309, Transcriptional Activity, mRNA Expression, and Survival in Stage I Non-Small-Cell Lung Cancer Patients with Wild-Type p53 Tumors

Authors: Wen-Pin Chien, PhD, Ruey-Hong Wong, PhD, Ya-Wen Cheng, PhD, Chih-Yi Chen, MD, PhD, Huei Lee, PhD

Published in: Annals of Surgical Oncology | Issue 4/2010

Login to get access

Abstract

Background

Mouse double minute 2 (MDM2) is a negative regulator of p53. In the present study, we examined MDM2 transcriptional activity and messenger RNA (mRNA) expression in lung tumors with respect to MDM2 SNP309 genotypes and p53 mutation status, and the effects of MDM2 SNP309 genotypes and p53 mutation status on lung cancer prognosis.

Methods

p53-null lung cancer cells were cotransfected with MDM2 P2 reporter construct containing the TT or GG genotype and wild-type or mutant p53 plasmids for luciferase reporter assay. Genomic DNA from 306 lung tumors and adjacent normal tissues was used to determine p53 mutation and MDM2 genotype by direct sequencing and polymerase chain reaction (PCR) restriction fragment length polymorphism. Real-time reverse-transcriptase PCR was applied to determine MDM2 mRNA levels. Overall survival was also calculated.

Results

Transcriptional activity of the MDM2 promoter containing the SNP309 GG genotype was significantly lower than that containing the TT genotype in p53-null lung cancer cells cotransfected with wild-type p53 expression plasmid under mithramycin A treatment. MDM2 mRNA levels in tumors with the SNP309 TG and GG genotypes were higher than those in tumors with the TT genotype, particularly in wild-type p53 tumors. Stage I patients with MDM2 SNP309 GG also had better overall survival than TT carriers, especially wild-type p53 patients (hazard ratio = 0.34; 95% confidence interval 0.15–0.80). Similar results were not observed in late-stage patients.

Conclusions

MDM2 SNP309 was associated with MDM2 transcripts, mRNA levels, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors.
Literature
1.
Menendez D, Inga A, Jordan JJ, Resnick MA. Changing the p53 master regulatory network: ELEMENTary, my dear Mr Watson. Oncogene. 2007;26:2191–201.CrossRefPubMed
2.
Tomizawa Y, Kohno T, Fujita T, et al. Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma. Oncogene. 1999;18:1007–14.CrossRefPubMed
3.
Ahrendt SA, Hu Y, Buta M, et al. p53 mutations and survival in stage I non-small-cell lung cancer: results of a prospective study. J Natl Cancer Inst. 2003;95:961–70.PubMed
4.
Nelson HH, Wilkojmen M, Marsit CJ, Kelsey KT. TP53 mutation, allelism and survival in non-small cell lung cancer. Carcinogenesis. 2005;26:1770–3.CrossRefPubMed
5.
Schiller JH, Adak S, Feins RH, et al. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy. J Clin Oncol. 2001;19:448–57.PubMed
6.
Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene. 2005;24:2899–908.CrossRefPubMed
7.
Toledo F, Wahl GM. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer. 2006;6:909–23.CrossRefPubMed
8.
Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004;119:591–602.CrossRefPubMed
9.
Koutsodontis G, Tentes I, Papakosta P, Moustakas A, Kardassis D. Sp1 plays a critical role in the transcriptional activation of the human cyclin-dependent kinase inhibitor p21(WAF1/Cip1) gene by the p53 tumor suppressor protein. J Biol Chem. 2001;276:29116–25.CrossRefPubMed
10.
Hirata H, Hinoda Y, Kikuno N, Kawamoto K, Suehiro Y, Tanaka Y, Dahiya R. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma. Clin Cancer Res. 2007;13:4123–9.CrossRefPubMed
11.
Cattelani S, Defferrari R, Marsilio S, et al. Impact of a single nucleotide polymorphism in the MDM2 gene on neuroblastoma development and aggressiveness: results of a pilot study on 239 patients. Clin Cancer Res. 2008;14:3248–53.CrossRefPubMed
12.
Gryshchenko I, Hofbauer S, Stoecher M, et al. MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia. J Clin Oncol. 2008;26:2252–7.CrossRefPubMed
13.
Ohmiya N, Taguchi A, Mabuchi N, Itoh A, Hirooka Y, Niwa Y, Goto H. MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J Clin Oncol. 2006;24:4434–40.CrossRefPubMed
14.
Heist RS, Zhou W, Chirieac LR, et al. MDM2 polymorphism, survival, and histology in early-stage non-small-cell lung cancer. J Clin Oncol. 2007;25:2243–7.CrossRefPubMed
15.
Sanchez-Carbayo M, Socci ND, Kirchoff T, Erill N, Offit K, Bochner BH, Cordon-Cardo C. A polymorphism in HDM2 (SNP309) associates with early onset in superficial tumors, TP53 mutations, and poor outcome in invasive bladder cancer. Clin Cancer Res. 2007;13:3215–20.CrossRefPubMed
16.
Galic V, Willner J, Wollan M, et al., Common polymorphism in TP53 and MDM2 and relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas. Genes Chromosomes Cancer. 2007;46:239–47.CrossRefPubMed
17.
Ko JL, Cheng YW, Chang SL, Su JM, Chen CY, Lee H. MDM2 mRNA expression is a favorable prognostic factor in non-small-cell lung cancer. Int J Cancer. 2000;89:265–70.CrossRefPubMed
18.
Higashiyama M, Doi O, Kodama K, et al. MDM2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation. Br J Cancer. 1997;75:1302–8.PubMed
19.
Slack A, Chen Z, Tonelli R, Pule M, Hunt L, Pession A, et al. The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. Proc Natl Acad Sci USA. 2005;102:731–6.CrossRefPubMed
20.
Ko JL, Chiao MC, Chang, SL, Lin P, Lin JC, Sheu GT, Lee H. (2002) A novel p53 mutant retained functional activity in lung carcinomas. DNA Repair (Amst). 1:755–62.CrossRef
21.
Bond GL, Hirshfield KM, Kirchhoff T, et al. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res. 2006;66:5104–10.CrossRefPubMed
22.
Huang CC, Cheng YW, Chen MC, Lin YS, Chou MC, Lee H. Different p53 mutation patterns in colorectal tumors from smokers and nonsmokers. Environ Mol Mutagen. 2006;47:527–32.CrossRefPubMed
23.
Phelps M, Darley M, Primrose JN, Blaydes JP. p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells. Cancer Res. 2003;63:2616–23.PubMed
24.
Zhang X, Miao X, Guo Y, et al. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum Mutat. 2006;27:110–7.CrossRefPubMed
25.
Hu Z, Ma H, Lu D, et al. Genetic variants in the MDM2 promoter and lung cancer risk in a Chinese population. Int J Cancer. 2006;118:1275–8.CrossRefPubMed
26.
Bond GL, Levine AJ. A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans. Oncogene. 2007;26:1317–23.CrossRefPubMed
27.
Bond GL, Menin C, Bertorelle R, Alhopuro P, Aaltonen LA, Levine AJ. MDM2 SNP309 accelerates colorectal tumour formation in women. J Med Genet. 2006;43:950–2.CrossRefPubMed
28.
Royds JA, Iacopetta B. p53 and disease: when the guardian angel fails. Cell Death Differ. 2006;13:1017–26.CrossRefPubMed
29.
Lianes P, Orlow I, Zhang ZF, Oliva MR, Sarkis AS, Reuter VE, Cordon-Cardo C. Altered patterns of MDM2 and TP53 expression in human bladder cancer. J Natl Cancer Inst. 1994;86:1325–30.CrossRefPubMed
30.
Saito H, Tsujitani S, Oka S, Ikeguchi M, Maeta M, Kaibara N. The expression of murine double minute 2 is a favorable prognostic marker in esophageal squamous cell carcinoma without p53 protein accumulation. Ann Surg Oncol. 2002;9:450–6.CrossRefPubMed
31.
Courjal F, Cuny M, Rodriguez C, et al. DNA amplifications at 20q13 and MDM2 define distinct subsets of evolved breast and ovarian tumours. Br J Cancer. 1996;74:1984–9.PubMed
32.
Tanner B, Hengstler JG, Laubscher S, et al. mdm 2 mRNA expression is associated with survival in ovarian cancer. Int J Cancer. 1997;74:438–42.CrossRefPubMed
33.
Bond GL, Hu W, Levine A. A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Res. 2005;65:5481–4.CrossRefPubMed
34.
Oda K, Arakawa H, Tanaka T, et al. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell. 2000;102:849–62.CrossRefPubMed
35.
Menin C, Scaini MC, De Salvo GL, et al. Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. J Natl Cancer Inst. 2006;98:285–8.PubMedCrossRef
36.
Polsky D, Melzer K, Hazan C, et al. HDM2 protein overexpression and prognosis in primary malignant melanoma. J Natl Cancer Inst. 2002;23:1803–6.
37.
Tammemagi MC, McLaughlin JR, Bull SB. Meta-analyses of p53 tumor suppressor gene alterations and clinicopathological features in resected lung cancers. Cancer Epidemiol Biomarkers Prev. 1999;8:625–34.PubMed
Metadata
Title
Associations of MDM2 SNP309, Transcriptional Activity, mRNA Expression, and Survival in Stage I Non-Small-Cell Lung Cancer Patients with Wild-Type p53 Tumors
Authors
Wen-Pin Chien, PhD
Ruey-Hong Wong, PhD
Ya-Wen Cheng, PhD
Chih-Yi Chen, MD, PhD
Huei Lee, PhD
Publication date
01-04-2010
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 4/2010
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-009-0853-2

Other articles of this Issue 4/2010

Annals of Surgical Oncology 4/2010 Go to the issue

Gastrointestinal Oncology

Neoadjuvant Docetaxel, Capecitabine and Cisplatin (DXP) in Patients with Unresectable Locally Advanced or Metastatic Gastric Cancer

Healthcare Policy and Outcomes

Cost Modeling of Preoperative Axillary Ultrasound and Fine-Needle Aspiration to Guide Surgery for Invasive Breast Cancer

Breast Oncology

Lymphatic Drainage Patterns from the Treated Breast

Thoracic Oncology

Pathologic Response after Neoadjuvant Therapy is the Major Determinant of Survival in Patients with Esophageal Cancer

Pancreatic Tumors

Adjuvant Chemoradiation for Pancreatic Adenocarcinoma: The Johns Hopkins Hospital—Mayo Clinic Collaborative Study

Gynecologic Oncology

Microscopic Evaluation of Lymph-Node-Bearing Tissue in Early-Stage Cervical Cancer: A Dual-Institution Review